TokenPost·

Celldex Shares Slip 2% After Barzolvolimab Misses Goals in Atopic Dermatitis Trial

Your call?

A phase 2 atopic dermatitis study of barzolvolimab missed its primary and secondary endpoints. Celldex shares fell about 2% in after-hours trading Thursday, Nov. 19.

Share

More news